Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors

被引:8
|
作者
Dansinger, Michael L. [1 ,2 ]
Williams, Paul T. [1 ]
Superko, H. Robert [1 ]
Schaefer, Ernst J. [1 ,3 ]
机构
[1] Boston Heart Diagnost, 175 Crossing Blvd,Suite 100, Framingham, MA 01702 USA
[2] Tufts Med Ctr, 800 Washington St, Boston, MA 02111 USA
[3] Tufts Univ, USDA, Human Nutr Res Ctr, Cardiovasc Nutr Lab, 711 Washington St, Boston, MA 02111 USA
关键词
Cholesterol; Triglyceides; Low-density lipoproteins; Apolipoprotein B; lipoprotein(a); Weight loss; Obesity; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; NON-HDL CHOLESTEROL; LDL-CHOLESTEROL; LARGE DATABASE; LIPIDS; PLASMA; LEVEL; RATIO; SUSCEPTIBILITY;
D O I
10.1186/s12944-019-1094-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background and aims Non-high-density (HDL)-cholesterol, low-density lipoprotein (LDL)-particle number, apolipoprotein B, lipoprotein(a) (Lp(a)), and small-dense (sdLDL) and large-buoyant (lbLDL) LDL-subfractions are emerging apo B-containing atherosclerotic cardiovascular disease (ASCVD) risk factors. Current guidelines emphasize lifestyle, including weight loss, for ASCVD risk management. Whether weight change affects these emerging risk factors beyond that predicted by traditional triglyceride and LDL-cholesterol measurements remains to be determined. Method Regression analyses of fasting apo B-containing lipoproteins vs. BMI were examined in a large anonymized clinical laboratory database of 33,165 subjects who did not report use of lipid-lowering medications. Regression slopes (SE) were estimated as: *mmol/L per kg/m(2), (dagger)g/L per kg/m(2), (double dagger)% per kg/m(2), and mu mol/L per kg/m(2). Results When adjusted for age, BMI was significantly related to nonHDL-cholesterol (males: 0.0238 +/- 0.0041, P=7.9x10(-9); females: 0.0330 +/- 0.0037, P<10(-16))*, LDL-particles (males: 0.0128 +/- 0.0024, P=2.1x10(-7); females: 0.0114 +/- 0.0022, P=3.2x10(-7))(*), apo B (males: 0.0053 +/- 0.0010, P=7.9x10(-8); females: 0.0073 +/- 0.0009, P=2.2x10(-16))(dagger), sdLDL (males: 0.0125 +/- 0.0015, P=2.2x10(-16); females: 0.0128 +/- 0.0012, P<10(-16))*, percent LDL carried on small dense particles (%sdLDL, males: 0.296 +/- 0.035, P<10(-16); females: 0.221 +/- 0.023, P<10(-16))(double dagger), triglycerides (males: 0.0358 +/- 0.0049, P=2.0x10(-13); females: 0.0304 +/- 0.0029, P<10(-16))*, and LDL-cholesterol (males: 0.0128 +/- 0.0034, P=0.0002; females: 0.0232 +/- 0.0031, P=1.2x10(-13))* in both males and females. Age-adjusted BMI was significantly related to lbLDL in females (0.0098 +/- 0.0024, P=3.9x10(-5))* but not males (0.0007 +/- 0.0026, P=0.78)*. Female showed significantly greater increases in LDL-cholesterol (P=0.02) and lbLDL (P=0.008) per BMI than males. BMI had a greater effect on LDL-cholesterol measured directly than indirect estimate of LDL-cholesterol from the Friedewald equation. When sexes were combined and adjusted for age, sex, triglycerides and LDL-cholesterol, BMI retained residual associations with nonHDL-cholesterol (0.0019 +/- 0.0009, P=0.03)*, LDL-particles (0.0032 +/- 0.0010, P=0.001)*, apo B (0.0010 +/- 0.0003, P=0.0008)(dagger), Lp(a) (-0.0091 +/- 0.0021, P=1.2x10(-5))(<section>), sdLDL (0.0001 +/- 0.0000, P=1.6x10(-11))(*) and %sdLDL (0.151 +/- 0.018, P<10(-16)) (double dagger). Conclusions Emerging apo B-containing risk factors show associations with weight change beyond those explained by the more traditional triglyceride and LDL-cholesterol measurements.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors
    Michael L. Dansinger
    Paul T. Williams
    H. Robert Superko
    Ernst J. Schaefer
    Lipids in Health and Disease, 18
  • [2] Physiochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease
    Rosenson, R. S.
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (04) : 316 - 319
  • [3] Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis
    Knowlton, N.
    Wages, J. A.
    Centola, M. B.
    Giles, J.
    Bathon, J.
    Quiroga, C.
    Alaupovic, P.
    ARTHRITIS CARE & RESEARCH, 2012, 64 (07) : 993 - 1000
  • [4] Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
    Paul D. Rosenblit
    Current Diabetes Reports, 2019, 19
  • [5] Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
    Rosenblit, Paul D.
    CURRENT DIABETES REPORTS, 2019, 19 (08)
  • [6] Predicting the risk of atherosclerotic cardiovascular disease (ASCVD) in Pakistani population
    Hassan, Khursheed
    Mohydin, Bilal
    Fawwad, Asher
    Waris, Nazish
    Iqbal, Samer
    Jawaid, Masood
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2019, 7 (02): : 184 - 187
  • [7] Predicting Atherosclerotic Cardiovascular Disease (ASCVD) Risk in Veterans with Diabetes
    Raghavan, Sridharan
    Ho, Yuk-Lam
    Posner, Daniel
    Vassy, Jason L.
    Gagnon, David R.
    Phillips, Lawrence S.
    Wilson, Peter W.
    DIABETES, 2019, 68
  • [8] Atherosclerotic cardiovascular disease: Emerging laboratory risk factors - Preface
    Smith, Donald A.
    CLINICS IN LABORATORY MEDICINE, 2006, 26 (03) : IX - XI
  • [9] Hypoglycemia and Risk of Atherosclerotic Cardiovascular Disease (ascvd) in Patients With Diabetes
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Karter, Andrew
    CIRCULATION, 2020, 142
  • [10] Correction to: Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
    Paul D. Rosenblit
    Current Diabetes Reports, 2019, 19